Business description: Cerus Corporation

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Number of employees: 268

Sales by Activity: Cerus Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Blood Safety

131M 162M 156M 180M 206M

Geographical breakdown of sales: Cerus Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States

67.5M 101M 93.23M 111M 125M

Other Countries

42.47M 41.33M 44.64M 49.5M 60.21M

France

20.89M 19.33M 18.49M 19.69M 21.2M

Executive Committee: Cerus Corporation

Manager TitleAgeSince
Chief Executive Officer 51 2026-06-30
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer - -

Composition of the Board of Directors: Cerus Corporation

Director TitleAgeSince
Chairman 59 2026-03-15
Director/Board Member 72 2014-03-23
Director/Board Member 51 2026-06-30
Director/Board Member 66 2018-10-08
Director/Board Member 67 2019-03-03
Director/Board Member 39 2021-08-03
Director/Board Member 65 2022-06-30
Director/Board Member 57 2024-06-30

Shareholders: Cerus Corporation

NameStocks%Valuation
BlackRock Advisors LLC
10.62 %
21,392,180 10.62 % 56 M $
ARK Investment Management LLC
8.898 %
17,932,099 8.898 % 47 M $
Vanguard Capital Management LLC
4.249 %
8,563,424 4.249 % 23 M $
Baker Bros. Advisors LP
3.174 %
6,395,431 3.174 % 17 M $
D.E. Shaw & Co., Inc.
2.722 %
5,485,983 2.722 % 14 M $

Company details: Cerus Corporation

Cerus Corp.

1220 Concord Avenue

94520, Concord

+925 288 6000

http://www.cerus.com
address Cerus Corporation(CERS)

Medical Devices & Implants

Change 5-day change 1-year change 3-year change Capi.($)
+0.38%-1.88%+69.48%+74.00% 526M
-1.34%-3.71%-27.33%-5.44% 103B
-1.04%-3.18%-24.58%-4.39% 11.17B
+0.91%-4.05%+87.08%+105.74% 9.13B
-1.29%+3.90%-49.08%-66.54% 4.14B
-0.91%+6.85%-24.92%+29.07% 2.49B
-3.28%+5.47% - - 1.94B
-0.36%-5.40%-11.59%-62.81% 1.99B
-1.43%+1.02%-22.05%-27.50% 1.53B
Average -0.92%-0.86%-0.38%+5.27% 15.15B
Weighted average by Cap. -1.16%-3.19%-19.29%+0.16%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.610USD
Average target price
5.125USD
Spread / Average Target
+96.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock
  4. Company Cerus Corporation